Dr. Steven Gray

Steven Gray graduated from Trinity College Dublin in 1992. He joined the laboratory of Tomas J. Ekstrom at the Karolinska Institute in 1996 and received his PhD in 2000 (Thesis Title: The IGF-axis in liver disease: Modulation of expression by histone deacetylase inhibitors). He moved to the Van Andel Research Institute in Michigan, USA where he continued his studies on the therapeutic potential of histone deacetylase inhibitors in the treatment of cancer. He also spent some time as a visting fellow at Harvard Medical School, Boston working on epigenetic therapies for neurodegenerative disease. Returning to Europe Dr Gray spent some time at the German Cancer Research Centre (DKFZ - Heidelberg), and subsequently moved to Copenhagen to work for Novo Nordisk as part of the research team of Prof Pierre De Meyts at the Hagedorn Research Institute working on epigenetic mechanisms underpinning diabetes pathogenesis. Dr Gray is currently a senior clinical scientist at St James's Hospital in the Deprtment of Clinical Oncology at the Thoraacic Oncology Research Group at St. James's Hospital headed by Dr. Sinead Cuffe and Professor Stephen Finn, and holds an adjunct assistant professorship with the Dept of Clinical Medicine (TCD).

  CANCER   CANCER BIOPSIES   CANCER CELL-LINE   CANCER CELLS   CANCER CHEMOTHERAPY   CANCER CLASSIFICATION   CANCER DEVELOPMENT   CANCER INVASION   CANCER SUSCEPTIBILITY GENE   CANCER-CELLS   CANCERS   CARCINOMA   CARCINOMA CELL-LINES   CARCINOMA, RENAL CELL   CARCINOMA-CELLS   CARCINOMAS   CELL   Cellular Biology   CHROMATIN   Cloning of Cells   Cytogenetics   DNA MARKERS   DNA METHYLATION   EPIDERMAL GROWTH FACTOR RECEPTOR   Epigenetics   GENE EXPRESSION   GENE EXPRESSION ANALYSIS   GENE-EXPRESSION   Genetics   GENOME   Genomes, Genomics   GENOMICS   GROWTH FACTOR RECEPTOR   Histology   Histology, Cytochemistry, Histochemistry   HISTONE   HISTONE DEACETYLASE COMPLEX   INSULIN   INSULIN RESISTANCE   INSULIN-LIKE GROWTH FACTOR I AND II   Life Sciences   METASTASIS   Molecular Biology   Molecular Genetics   Systematic Biology   Tissue Culture   Transcription

My research mainly involves using epigenetic targeting agents to examine fundamental mechanisms underpinning the regulation of (i) Receptor Tyrosine Kinases (RTKs); (ii) inflammation and (iii) cellular metabolism in thoracic malignancy and to study their potential therapeutic efficacy in the treatment of lung cancer and mesothelioma. Research in my laboratory also tries to understand the role of epigenetics and epigenetic mechanisms underpinning drug resistance in lung cancer and mesothelioma. In addition to the above my research also involves the study of non-coding RNA repertoires (lncRNAs and circRNAs) in lung cancer and mesothelioma for their potential utility as candidate biomarkers for the early prediction of thoracic malignancy, and to study their roles in lung cancer biogenesis and resistance to therapy.